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A. Introduction
In this project, we are developing a new technique for stimulating a patient's own immune system as a therapeutic approach for the treatment of cancer in general, and prostate cancer, in particular. Thus far, immunotherapeutic protocols for treating cancer (including prostate cancer) in the clinical setting have not been uniformly successful 1 . Many of these methods have been directed toward the stimulation of a CD8+ T-cell response in the host, but have lacked a mechanism for vigorous immune system stimulation and have not combined CD4+ T-cell responses or B-cell involvement 2 . Recently, techniques involving stimulation of dendritic cells (DC) with tumor antigens have begun to show promise, but the process involves isolation of DCs and in vitro stimulation, followed by re-injection into the patient. Our methodology uses direct in vivo stimulation/maturation of DCs via Toll-like receptors (TLRs) 3 5 . We are chemically synthesizing molecular conjugates that comprise a TLR ligand covalently linked to a prostate cancer tumor-associated antigen protein or peptide. Using this tactic, we anticipate that the TLR-ligand portion of the conjugates will stimulate DCs (as well as other TLR-expressing antigen presenting cells) to secrete immuneactivating cytokines while the tumor antigen component of the complex will be processed and presented to activated T cells. We have addressed the synthesis of conjugates based on TLR-2 and TLR-7 ligands. The prostate cancer antigen portion of the complexes currently includes an MHC Class I peptide epitope from prostate-specific membrane antigen (PSMA) 6 and a general MHC Class II peptide epitope (PADRE) 7 ' 8 . We have included the complete prostate-specific antigen (PSA) protein linked to a TLR-7 ligand. Our conjugates represent a new and potent immune system stimulation and antigen presentation mechanism with in vivo activation of DCs aimed at the stimulation of combined CD8+ and CD4+ T-cell responses along with B-cell activation through the innate/adaptive immune response connection. The conjugates are designed to elicit a vigorous immune response to prostate cancer, and may be administered by s.c. injection, or possibly, nasal or oral routes.
B. Body
This section describes research accomplishments associated with the tasks outlined in the original award application for Year Three of the project.
Task 1. Synthesize lipopeptide carriers covalently conjugated to PSA protein (months 1-14)
From previous effort we have completed the synthesis of the antigen conjugates in Figure 1 using the synthetic route outlined in Scheme 1.
in Scheme 2. The PSMA immunostimulatory conjugates are based upon the human PSMA HLA-A2 restricted peptide epitope (ALFDIESKV) and incorporate an aminohexyl spacer between the peptide epitope and a terminal cysteine for attachment to the TLR ligands. The PADRE conjugates comprise the general CD4+ restricted peptide epitope PADRE 7 ' 8 using the identical aminohexyl functionality bonded to a terminal cysteine (aK-clohexylalanine-VAAWTLKAAa-aminohexyl-C). We also synthesized the PSMA epitope covalently linked to the PADRE peptide through a central cysteine (aK-cyclohexylalanine-VAAWTLKAAa-C-ALFDIESKV) in order to evaluate the immunogenicity of conjugates, which contain both MHC Class I and MHC Class II epitopes. The TLR-2 ligand (PAM 3cys) lipopeptide conjugates proved to be quite insoluble, and thus far we have been unable to either adequately purify the materials or obtain mass spectral characterization data using MALDI, ESI or FAB ionization techniques. Similar difficulties have been noted recently for other PAM 3 -cys-peptide conjugates . For this reason, we are using the TLR-7-1igand conjugates of Figure 1 and Scheme 2 in our immunization experiments.
Taskl2. Immunize HLA-DR4 and HLA-A2 transgenic mice with lipopeptide-PSA conjugates. Analyze immune responses and test responses against prostate cancer cell-lines (months 9-25)
Having prepared immunostimulating conjugates, we began mouse immunization experiments. Founder homozygous mice carrying the HLA-A2.1 Enge transgene that express the human class MHC Class I antigen HLA-A2. 1 on cells from the spleen, bone marrow and thymus were obtained from Jackson laboratories, Bar Harbor, ME (Stock Number: 003475). This surface protein recognizes the PSMA peptide epitope that is incorporated into our conjugates. A breeding colony of these mice has been established at The University of Utah. Since wc have included the generalized human and mouse MiC Class II antigenic peptide epitope PADRE in our conjugate evaluation, it was not necessary to utilize transgenic mice expressing human HLA-DR4 as originally proposed.
conjgats. nalze mmue repones nd estresonse agins prstae cnce
The PADRE peptide is expected to provide the desired CD4+ helper T-cell stimulation. Mice in groups of three were immunized (s.c., axilla) with the TLR-7 ligand PSMA-PADRE conjugate ( Figure 2 ). Three levels of conjugate were initially examined (0.1, 1.0, and 10 [tg). Mice were also immunized with the unconjugated PSMA, PADRE, and PSMA-PADRE peptides. Syngenetic C57BL/6J mice that do not express the HLA-A2 gene were used as controls. Twenty-eight days after the initial immunization, each group of mice received a boost vaccination. Eleven days post-boost, splenocytes and peripheral lymph node (PLN) lymphocytes were harvested and [ 3 H]-thymidine cell proliferation assays were performed. Each cell population was administered [ 3 H]-thymidine, stimulated with antigenic peptides (10, 15, 7.5, and 3.8 jtg/ml) and controls, and incubated for 24 h. Radioactivity incorporation compared to controls was taken as an indication of the expansion of the cell population in response to antigenic peptide stimulation. Figure 3 summarizes our most recent results. Our previous work used a minimum of 0.1 jtg vaccination. We therefore repeated the immunization protocol using a vaccination dose of only 0.01 ltg. Figure 2 summarizes these results. It is apparent that even this low amount of antigen also primes lymphocytes in this mouse model. This compares with Figure 4 which shows that even at 1000 times the amount (10 jtg) of the PSMA-PADRE peptide (without the covalently attached TLR-7 ligand) elicits no response. This indicates the powerful immunostimulatory effects of the Toll-like receptor-antigen conjugate approach to cancer immunotherapy. In preparation for these experiments, we experienced difficulty with the uptake and retention of 51 Cr by the LNCaP cells using standard labeling protocols. Our first approach to the problem was to obtain different batches of the LNCaP (ATCC) cells. These cells were also found to be difficult to 51 Cr label. We then searched for an alternate human prostate cancer cell line that expressed both PSA and PSMA as well as being HLA-A2.1 positive. Several cell lines were evaluated by immunostaining for the necessary markers but we were unable to identify a suitable alternate cell line. We then turned our attention back to the LNCaP cells.
After numerous attempts using multiple cell culture media/conditions (with and without sex hormone supplementation) , we identified circumstances (RPMI with 10% FCS, complemented with non-essential amino acids, sodium pyruvate, mercaptoethanol, and glutamine) which resulted in good cell growth and cells that were readily 51 Cr labeled and, importantly, retained the radiolabel. We are now back on track with our immunization experiments and CTL evaluation. Because of these delays, we have requested a no cost extension of the program in order to complete all these originally proposed immunological evaluations. In view of our earlier difficulties with the PSA protein conjugates, we have replaced the PSMA protein-conjugate work with relevant PSMA peptide epitope experiments. These conjugates were synthesized ( Figure 1) and their evaluation has been incorporated into Task 2 which is underway.
C. Key Research Accomplishments
This section provides a list of key accomplishments to date of this research. " Functionalized ligands recognized by TLR-2 and TLR-7 have been prepared.
These ligands were chemically modified with thiol-reactive haloacetamide functionality for attachment of cysteine-containing antigenic proteins and peptides.
"* TLR-7 and TLR-2 ligand-antigenic peptide conjugates have been prepared as well as a TLR-7-ligand PSA protein conjugate. "* Mouse immunization experiments are in progress.
Data indicate an immunogenic response to the antigenic epitopes.
D. Reportable Outcomes
This program supports graduate research assistant, Mr. Jiang Sha, and the results from his research will be incorporated into his dissertation.
E. Conclusions
Research on this program thus far has provided modified TLR-2 and TLR-7 ligands suitable for chemical attachment of prostate cancer associated antigenic peptides and proteins. The resulting immunostimulating conjugates are being evaluated in mouse immunization experiments in order to ascertain the production of CD8+ and CD4+ T-cells as well as antibodies specific to prostate cancer antigens.
This research is significant in that it represents the first attempt to generate a host immune response to prostate cancer antigens using the potent immune system activation that arises from the innate/adaptive response connection from targeted TLR signaling in combination with antigen presentation. Evaluation of the separate conjugates will provide new insight into the effectiveness of the immune response to the same antigen stimulated by different TLRs. Such effects are not yet known.
Furthermore, the possibility of an increased immune response to cancer antigens presented simultaneously with more than one TLR receptor activation path has not been explored. With our newly-synthesized conjugates, we are in a position to initiate these exciting studies.
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